Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.

Dziadziuszko R, Ahn JS, Barlesi F, Solomon BJ, Wu YL, Bondarenko I, Hochmair M, Horinouchi H, Lee DH, Lee JS, Planchard D, Rittmeyer A, Zhong W, Adler L, Archer V, Cardona A, Petric P, Scalori A, Ding B, Mamolo C, Smoljanovic V, Nishio M

Open source

DOI: 10.1016/s1470-2045(26)00283-4
Published: 2026 Sep
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00283-4,
  title = {Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.},
  author = {Dziadziuszko R and Ahn JS and Barlesi F and Solomon BJ and Wu YL and Bondarenko I and Hochmair M and Horinouchi H and Lee DH and Lee JS and Planchard D and Rittmeyer A and Zhong W and Adler L and Archer V and Cardona A and Petric P and Scalori A and Ding B and Mamolo C and Smoljanovic V and Nishio M},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(26)00283-4},
  url = {https://doi.org/10.1016/s1470-2045(26)00283-4}
}

RIS

TY  - JOUR
TI  - Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.
AU  - Dziadziuszko R
AU  - Ahn JS
AU  - Barlesi F
AU  - Solomon BJ
AU  - Wu YL
AU  - Bondarenko I
AU  - Hochmair M
AU  - Horinouchi H
AU  - Lee DH
AU  - Lee JS
AU  - Planchard D
AU  - Rittmeyer A
AU  - Zhong W
AU  - Adler L
AU  - Archer V
AU  - Cardona A
AU  - Petric P
AU  - Scalori A
AU  - Ding B
AU  - Mamolo C
AU  - Smoljanovic V
AU  - Nishio M
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(26)00283-4
UR  - https://doi.org/10.1016/s1470-2045(26)00283-4
ER  -

APA

R, D., JS, A., F, B., BJ, S., YL, W., I, B., M, H., H, H., DH, L., JS, L., D, P., A, R., W, Z., L, A., V, A., A, C., P, P., A, S., B, D., C, M., V, S., & M, N. (2026). Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00283-4

Source records

pubmed · retrieved 2026-09-25T20:50:37.078Z